10,000 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Bought by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 3rd quarter, HoldingsChannel reports. The institutional investor bought 10,000 shares of the biotechnology company’s stock, valued at approximately $1,493,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its stake in shares of Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Ascendis Pharma A/S by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock valued at $1,664,000 after purchasing an additional 4,338 shares during the last quarter. Evolutionary Tree Capital Management LLC boosted its position in shares of Ascendis Pharma A/S by 82.3% during the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock worth $3,391,000 after purchasing an additional 11,223 shares during the period. SG Americas Securities LLC grew its stake in shares of Ascendis Pharma A/S by 221.0% in the second quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock valued at $833,000 after buying an additional 4,205 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Ascendis Pharma A/S by 1,461.1% in the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after purchasing an additional 234,446 shares in the last quarter.

Ascendis Pharma A/S Stock Down 0.1 %

ASND stock traded down $0.15 during mid-day trading on Thursday, reaching $125.88. The company had a trading volume of 15,384 shares, compared to its average volume of 441,269. The stock’s 50-day simple moving average is $132.04 and its two-hundred day simple moving average is $132.86. The stock has a market capitalization of $7.63 billion, a P/E ratio of -13.54 and a beta of 0.66. Ascendis Pharma A/S has a one year low of $90.13 and a one year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, research analysts forecast that Ascendis Pharma A/S will post -7.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. JPMorgan Chase & Co. cut their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a report on Monday, November 4th. Bank of America lifted their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. The Goldman Sachs Group upped their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Finally, Evercore ISI boosted their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $195.92.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.